{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05375994",
            "orgStudyIdInfo": {
                "id": "VS-6766-204"
            },
            "organization": {
                "fullName": "Verastem, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients",
            "officialTitle": "A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Adagrasib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 204)",
            "acronym": "RAMP204",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "study-of-avutometinib-vs-adagrasib-in-kras-nsclc-patients"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-08-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-07-24",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-01-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-05-02",
            "studyFirstSubmitQcDate": "2022-05-10",
            "studyFirstPostDateStruct": {
                "date": "2022-05-17",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-07-19",
            "lastUpdatePostDateStruct": {
                "date": "2023-07-21",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Verastem, Inc.",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Mirati Therapeutics Inc.",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced progressive disease.",
            "detailedDescription": "This is a multicenter, non-randomized, open-label Phase 1/2 study designed to evaluate safety, tolerability and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with KRAS G12C mutant NSCLC who have been exposed to prior G12C inhibitor and experienced progressive disease."
        },
        "conditionsModule": {
            "conditions": [
                "Non Small Cell Lung Cancer",
                "KRAS Activating Mutation",
                "Advanced Cancer",
                "Metastatic Cancer",
                "Malignant Neoplasm of Lung",
                "Malignant Neoplastic Disease"
            ],
            "keywords": [
                "NSCLC",
                "KRAS G12C",
                "Non Small Cell Lung Cancer",
                "Metastatic Cancer",
                "Adagrasib",
                "Avutometinib (VS-6766)"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 85,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "avutometinib(VS-6766)+adagrasib",
                    "type": "EXPERIMENTAL",
                    "description": "To determine the recommended phase 2 dose (RP2D) for VS-6766 in combination with adagrasib in G12C inhibitor exposed patients",
                    "interventionNames": [
                        "Drug: avutometinib (VS-6766) and adagrasib"
                    ]
                },
                {
                    "label": "avutometinib (VS-6766)+adagrasib RP2D",
                    "type": "EXPERIMENTAL",
                    "description": "To determine the efficacy of the RP2D identified from Part A in G12C inhibitor exposed patients",
                    "interventionNames": [
                        "Drug: avutometinib (VS-6766) and adagrasib"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "avutometinib (VS-6766) and adagrasib",
                    "description": "The RP2D of VS-6766 + adagrasib determined in Part A will be used in Part B dose expansion",
                    "armGroupLabels": [
                        "avutometinib (VS-6766)+adagrasib RP2D",
                        "avutometinib(VS-6766)+adagrasib"
                    ],
                    "otherNames": [
                        "KRAS G12C Inhibitor, adagrasib, KRAZATI\u00ae"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Part A: To determine RP2D for avutometinib(VS-6766) in combination with adagrasib",
                    "description": "Assessment of Dose-limiting toxicities (DLTs)",
                    "timeFrame": "From start of treatment to confirmation of RP2D; 28 days"
                },
                {
                    "measure": "To determine the efficacy of the optimal regimen identified from Part A",
                    "description": "Confirmed overall response rate per RECIST 1.1",
                    "timeFrame": "From start of treatment to confirmation of response; 16 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "To characterize the safety and toxicity profile:",
                    "description": "* Incidence of Adverse events (AEs) and Serious Adverse Events (SAEs) assessed by the toxicity grading of the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v 5.0)\n* Severity of Adverse events (AEs) and Serious Adverse Events (SAEs) by toxicity grade assessed by the toxicity grading of the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v 5.0)\n* Duration of Adverse events (AEs) and Serious Adverse Events (SAEs)\n* Incidence of clinically significant changes in lab parameters\n* Incidence of abnormal vital signs (including systolic and diastolic blood pressure in mmHg)",
                    "timeFrame": "24 Months"
                },
                {
                    "measure": "ECG QT Interval",
                    "description": "Corrected ECG QT interval by Fredericia (QTcF)",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "Duration of Response (DOR)",
                    "description": "Time of first response to PD as assessed per RECIST 1.1",
                    "timeFrame": "Time from the first documentation of response to first documentation of progressive disease or death due to any cause, greater than or equal to 6 months"
                },
                {
                    "measure": "Disease Control Rate (DCR)",
                    "description": "CR and PR stable disease as assessed per RECIST 1.1",
                    "timeFrame": "Greater than or equal to 8 weeks"
                },
                {
                    "measure": "Progression Free Survival (PFS)",
                    "description": "From the time of first dose of study intervention to PD or death from any cause",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "Overall Survival (OS)",
                    "description": "From time of first dose of study intervention to death",
                    "timeFrame": "Up to 5 years"
                },
                {
                    "measure": "Plasma Pharmacokinetics (PK) of avutometinib(VS 6766), adagrasib, and relevant metabolites - Tmax",
                    "description": "time of Maximum concentration (Tmax)",
                    "timeFrame": "10 weeks"
                },
                {
                    "measure": "Plasma Pharmacokinetics (PK) of avutometinib(VS 6766), adagrasib, and relevant metabolites - AUC",
                    "description": "Area under plasma Concentration (AUC) 0 to t",
                    "timeFrame": "10 weeks"
                },
                {
                    "measure": "Plasma Pharmacokinetics (PK) of avutometinib(VS 6766), adagrasib, and relevant metabolites - Half-life",
                    "description": "concentration Half-life (T1/2)",
                    "timeFrame": "10 weeks"
                },
                {
                    "measure": "Clinical Benefit Rate",
                    "description": "defined as Complete Response+Partial Response +Stable Disease",
                    "timeFrame": "\u2265 6 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female subjects \u2265 18 years of age\n* Histologic or cytologic evidence of NSCLC\n* Known KRAS G12C mutation\n* The subject must have received prior therapy with a KRAS G12C inhibitor and experienced progression\n* Must have received appropriate treatment with at least one prior systemic regimen, but no more than 3 prior regimens, for Stage 3B-C or 4 NSCLC\n* Measurable disease according to RECIST 1.1\n* An Eastern Cooperative Group (ECOG) performance status \u2264 1\n* Adequate organ function\n* Adequate recovery from toxicities related to prior treatments\n* Agreement to use highly effective method of contraceptive\n\nExclusion Criteria:\n\n* Prior chemotherapy, targeted therapies, radiotherapy, immunotherapy or treatment with an investigational agent within 14 days of receipt of study drug (within 6 weeks for nitrosoureas, mitomycin C and chest radiation; within 6 months prior to Cycle 1 Day 1 for chest radiation \\> 30Gy)\n* History of prior malignancy, with the exception of curatively treated malignancies\n* Major surgery within 4 weeks (excluding placement of vascular access)\n* Exposure to strong CYP3A4 inhibitors or inducers within 14 days prior to the first dose and during the course of therapy\n* Exposure to strong inhibitors of breast cancer resistance protein (BCRP) within 14 days prior to the first dose and during the course of therapy\n* Symptomatic brain metastases requiring steroids or other local interventions within the 2 weeks prior to initiation of therapy\n* Known SARS-Cov2 infection \u226428 days prior to first dose of study therapy\n* Known hepatitis B, hepatitis C, or human immunodeficiency virus infection that is active\n* Active skin disorder that has required systemic therapy within the past 1 year\n* History of rhabdomyolysis or interstitial lung disease\n* Concurrent ocular disorders\n* Concurrent heart disease or severe obstructive pulmonary disease\n* Subjects with the inability to swallow oral medications",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Verastem Call Center",
                    "role": "CONTACT",
                    "phone": "1 781 292 4204",
                    "email": "clinicaltrials@verastem.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "MD Verastem",
                    "affiliation": "Verastem, Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "UCSF Thoracic Oncology",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94158",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Bianca Bacaltos",
                            "role": "CONTACT",
                            "phone": "415-885-3526",
                            "email": "Bianca.Bacaltos@ucsf.edu"
                        },
                        {
                            "name": "Collin Blakely, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "University of Colorado Hospital Anschutz Cancer Pavllion",
                    "status": "RECRUITING",
                    "city": "Aurora",
                    "state": "Colorado",
                    "zip": "80045",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Halle Kuykendall",
                            "role": "CONTACT",
                            "phone": "720-848-0356",
                            "email": "halle.kuykendall@cuanschutz.edu"
                        },
                        {
                            "name": "David Camidge, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.72943,
                        "lon": -104.83192
                    }
                },
                {
                    "facility": "Mayo Clinic Cancer Center",
                    "status": "RECRUITING",
                    "city": "Jacksonville",
                    "state": "Florida",
                    "zip": "32224",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Yanyan Lou",
                            "role": "CONTACT",
                            "phone": "855-776-0015",
                            "email": "lou.yanyan@mayo.edu"
                        },
                        {
                            "name": "YanYan Lou, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.33218,
                        "lon": -81.65565
                    }
                },
                {
                    "facility": "Mayo Clinic Cancer Center",
                    "status": "RECRUITING",
                    "city": "Rochester",
                    "state": "Minnesota",
                    "zip": "55905",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kaushal Parikh",
                            "role": "CONTACT",
                            "phone": "855-776-0015",
                            "email": "parikh.kaushal@mayo.edu"
                        },
                        {
                            "name": "Kaushal Parikh, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.02163,
                        "lon": -92.4699
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kathryn Arbour, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "University of North Carolina at Chapel Hill",
                    "status": "RECRUITING",
                    "city": "Chapel Hill",
                    "state": "North Carolina",
                    "zip": "275514",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Bryana Roberts",
                            "role": "CONTACT",
                            "phone": "919-966-4432",
                            "email": "bryana_roberts@med.unc.edu"
                        },
                        {
                            "name": "Jared Weiss, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.9132,
                        "lon": -79.05584
                    }
                },
                {
                    "facility": "Virginia Cancer Specialists, NEXT Oncology",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "MaryAnn Poole",
                            "role": "CONTACT",
                            "phone": "703-280-5390",
                            "email": "mpoole@nextoncology.com"
                        },
                        {
                            "name": "Alexander Spira, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                },
                {
                    "facility": "Medical College Wisconsin",
                    "status": "RECRUITING",
                    "city": "Milwaukee",
                    "state": "Wisconsin",
                    "zip": "53226",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Nicholas Pucek",
                            "role": "CONTACT",
                            "phone": "414-805-3158",
                            "email": "npucek@mcw.edu"
                        },
                        {
                            "name": "Hui-Zi Chen, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.0389,
                        "lon": -87.90647
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008175",
                    "term": "Lung Neoplasms"
                },
                {
                    "id": "D000002289",
                    "term": "Carcinoma, Non-Small-Cell Lung"
                },
                {
                    "id": "D000009362",
                    "term": "Neoplasm Metastasis"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000002283",
                    "term": "Carcinoma, Bronchogenic"
                },
                {
                    "id": "D000001984",
                    "term": "Bronchial Neoplasms"
                },
                {
                    "id": "D000009385",
                    "term": "Neoplastic Processes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "asFound": "Non-small Cell Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "asFound": "Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "asFound": "Metastatic Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5540",
                    "name": "Carcinoma, Bronchogenic",
                    "relevance": "LOW"
                },
                {
                    "id": "M5260",
                    "name": "Bronchial Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M12330",
                    "name": "Neoplastic Processes",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000718190",
                    "term": "Adagrasib"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M288000",
                    "name": "Adagrasib",
                    "asFound": "Topical steroid",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}